Literature DB >> 1868493

Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2.

M R Berger1, M Salas, F Garzon, E Petru, U Schwulera, D Schmähl.   

Abstract

The antineoplastic efficacy of human interleukin-2 (IL-2) in autochthonous methylnitrosourea-induced mammary carcinoma and in acetoxymethyl-methyl-nitrosamine-induced colorectal carcinoma of Sprague Dawley rats has been investigated. Under the conditions applied, IL-2 was non-toxic. In the mammary carcinoma IL-2 was therapeutically inactive. In the colorectal carcinoma, 1200 U IL-2/day exhibited significant antitumour activity in established tumours as well as in tumours treated "prophylactically" before their manifestation (P less than 0.05). The effect of IL-2 seemed to be more pronounced when given before manifestation of colorectal tumours (T/C = 8.7% vs 17.8% in established tumours). The differential sensitivity of the autochthonous mammary and colorectal carcinoma may be explained by differences in their proliferation rates and differences in volumes at the beginning of IL-2 therapy. IL-2 seems to be preferentially active in small tumours with a low proliferation rate, a feature typical of colon tumours.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868493     DOI: 10.1007/bf01756601

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment.

Authors:  J A Koziol; D A Maxwell; M Fukushima; M E Colmerauer; Y H Pilch
Journal:  Biometrics       Date:  1981-06       Impact factor: 2.571

2.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression.

Authors:  T Reissmann; P Hilgard; R Voegeli; J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.

Authors:  J A Thompson; D J Peace; J P Klarnet; D E Kern; P D Greenberg; M A Cheever
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

5.  Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.

Authors:  R Maekawa; M Matsumoto; T Kitagawa; M Harada; K Sato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.

Authors:  M Rodolfo; C Salvi; C Bassi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 7.  The clinical potential of interleukin-2.

Authors:  R T Oliver
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

8.  Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.

Authors:  A M Eggermont; P H Sugarbaker
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

9.  Effects of a combination of cyclophosphamide and human recombinant interleukin 2 on pulmonary metastasis after the surgical removal of a 3-methylcholanthrene-induced primary tumor in autochthonous mice.

Authors:  M Hosokawa; T Yabiku; J Ikeda; Y Sawamura; F Okada; M Komatsumoto; T Tanabe; H Kobayashi
Journal:  Jpn J Cancer Res       Date:  1988-10

10.  Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.

Authors:  S Mitsunaga; H Kimura; Y Yamaguchi; A Mikata
Journal:  Jpn J Cancer Res       Date:  1988-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.